🟢 Edesa Biotech is trading 5.1% up today on positive Phase 3 ARDS data and $3.5M PIPE financing

Edesa Biotech is trading 5.1% up today at $7.16, extending its rebound from the July 13 close as investors react to recent clinical and financing developments.

• The upward move is driven by ongoing positive sentiment surrounding additional Phase 3 paridiprubart ARDS mortality data released during the fiscal Q2 period.
• A $3.5 million PIPE financing led by the CEO and healthcare-focused investors has strengthened the balance sheet and validated institutional demand for the clinical program.